Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Gross Profit (2016 - 2025)

Historic Gross Profit for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Q3 2025 value amounting to $3.9 million.

  • Cumberland Pharmaceuticals' Gross Profit fell 1769.95% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.2 million, marking a year-over-year increase of 2569.78%. This contributed to the annual value of $20.8 million for FY2024, which is 121.24% down from last year.
  • Latest data reveals that Cumberland Pharmaceuticals reported Gross Profit of $3.9 million as of Q3 2025, which was down 1769.95% from $6.6 million recorded in Q2 2025.
  • Over the past 5 years, Cumberland Pharmaceuticals' Gross Profit peaked at $7.5 million during Q1 2025, and registered a low of $3.9 million during Q3 2025.
  • Moreover, its 5-year median value for Gross Profit was $5.6 million (2024), whereas its average is $5.6 million.
  • Its Gross Profit has fluctuated over the past 5 years, first crashed by 2683.8% in 2023, then surged by 7225.14% in 2025.
  • Quarter analysis of 5 years shows Cumberland Pharmaceuticals' Gross Profit stood at $5.0 million in 2021, then rose by 14.57% to $5.7 million in 2022, then dropped by 20.03% to $4.6 million in 2023, then soared by 35.25% to $6.2 million in 2024, then tumbled by 37.9% to $3.9 million in 2025.
  • Its Gross Profit stands at $3.9 million for Q3 2025, versus $6.6 million for Q2 2025 and $7.5 million for Q1 2025.